BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19448608)

  • 21. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
    Ribera JM; Oriol A; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M;
    Br J Haematol; 2008 Feb; 140(4):411-9. PubMed ID: 18162120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma.
    Sohn BS; Kim SM; Yoon DH; Kim S; Lee DH; Kim JH; Lee SW; Huh J; Suh C
    Ann Hematol; 2012 Nov; 91(11):1731-9. PubMed ID: 22752193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of gastrointestinal diffuse large B cell lymphoma in China: a 10-year retrospective study of 114 cases.
    Li X; Shen W; Cao J; Wang J; Chen F; Wang C; Zou S; Shen B; Zhao R; Li J; Shen Z
    Ann Hematol; 2012 Nov; 91(11):1721-9. PubMed ID: 22733613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients.
    Li JM; Wang L; Shen Y; Xia ZG; Chen Y; Chen QS; Chen Y; Zeng XY; You JH; Qian Y; Shen ZX
    Ann Hematol; 2007 Sep; 86(9):639-45. PubMed ID: 17572895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
    J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
    Copie-Bergman C; Gaulard P; Leroy K; Briere J; Baia M; Jais JP; Salles GA; Berger F; Haioun C; Tilly H; Emile JF; Banham AH; Mounier N; Gisselbrecht C; Feugier P; Coiffier B; Molina TJ
    J Clin Oncol; 2009 Nov; 27(33):5573-9. PubMed ID: 19786664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Glasgow Prognostic Score as a significant predictor of diffuse large B cell lymphoma treated with R-CHOP in China.
    Li X; Zhang Y; Zhao W; Liu Z; Shen Y; Li J; Shen Z
    Ann Hematol; 2015 Jan; 94(1):57-63. PubMed ID: 25085376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21.
    Scandurra M; Mian M; Greiner TC; Rancoita PM; De Campos CP; Chan WC; Vose JM; Chigrinova E; Inghirami G; Chiappella A; Baldini L; Ponzoni M; Ferreri AJ; Franceschetti S; Gaidano G; Montes-Moreno S; Piris MA; Facchetti F; Tucci A; Nomdedeu JF; Lazure T; Lambotte O; Uccella S; Pinotti G; Pruneri G; Martinelli G; Young KH; Tibiletti MG; Rinaldi A; Zucca E; Kwee I; Bertoni F
    Br J Haematol; 2010 Nov; 151(3):221-31. PubMed ID: 20813005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Wu PY; Zhang XD; Zhu J; Guo XY; Wang JF
    Hum Pathol; 2014 Aug; 45(8):1664-73. PubMed ID: 24931464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patients with diffuse large B cell lymphoma in partial response or stable disease after first-line R-CHOP: the prognostic value of the absolute lymphocyte count and impact of autologous stem cell transplantation.
    Hung MH; Yu YB; Huang YC; Liu HT; Hong YC; Hsiao LT; Liu JH; Gau JP; Chiou TJ; Chen PM; Tzeng CH; Liu CY
    Ann Hematol; 2012 Dec; 91(12):1907-15. PubMed ID: 22885989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens.
    Goto N; Tsurumi H; Kasahara S; Kanemura N; Hara T; Yasuda I; Shimizu M; Murakami N; Sawada M; Yamada T; Takemura M; Seishima M; Kito Y; Takami T; Moriwaki H
    Eur J Haematol; 2011 Sep; 87(3):217-27. PubMed ID: 21575062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy.
    Kim SJ; Lee SJ; Choi IY; Park Y; Choi CW; Kim IS; Yu W; Hwang HS; Kim BS
    Eur J Haematol; 2008 Sep; 81(3):177-84. PubMed ID: 18510703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients.
    Sar A; Perizzolo M; Stewart D; Mansoor A; Difrancesco LM; Demetrick DJ
    Leuk Res; 2009 Jun; 33(6):792-7. PubMed ID: 19054557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
    Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD
    J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.
    Meyer PN; Fu K; Greiner T; Smith L; Delabie J; Gascoyne R; Ott G; Rosenwald A; Braziel R; Campo E; Vose J; Lenz G; Staudt L; Chan W; Weisenburger DD
    Am J Clin Pathol; 2011 Jan; 135(1):54-61. PubMed ID: 21173124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP.
    Samaras P; Heider H; Haile SR; Petrausch U; Schaefer NG; Siciliano RD; Meisel A; Mischo A; Zweifel M; Knuth A; Stenner-Liewen F; Renner C
    Ann Hematol; 2010 Aug; 89(8):783-7. PubMed ID: 20204361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
    Habermann TM; Weller EA; Morrison VA; Gascoyne RD; Cassileth PA; Cohn JB; Dakhil SR; Woda B; Fisher RI; Peterson BA; Horning SJ
    J Clin Oncol; 2006 Jul; 24(19):3121-7. PubMed ID: 16754935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
    Feugier P; Van Hoof A; Sebban C; Solal-Celigny P; Bouabdallah R; Fermé C; Christian B; Lepage E; Tilly H; Morschhauser F; Gaulard P; Salles G; Bosly A; Gisselbrecht C; Reyes F; Coiffier B
    J Clin Oncol; 2005 Jun; 23(18):4117-26. PubMed ID: 15867204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic role of serum lactate dehydrogenase beyond initial diagnosis: a retrospective analysis of patients with diffuse large B cell lymphoma.
    Hong J; Yoon HH; Ahn HK; Sym SJ; Park J; Park PW; Ahn JY; Park S; Cho EK; Shin DB; Lee JH
    Acta Haematol; 2013; 130(4):305-11. PubMed ID: 24008775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14.
    Gutiérrez A; Bento L; Bautista-Gili AM; Garcia F; Martinez-Serra J; Sanchez B; Martorell C; Gines J; Garcia L; Gimeno E; Ferraro M; Del Campo R; Bargay J; Perez A; Vercher J; Scaff M; Pacheco A; Ballester C; Garcia F; Ramos R; Salar A; Besalduch J
    PLoS One; 2015; 10(4):e0123978. PubMed ID: 25909361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.